Vir Biotechnology director sells 3,200 shares

Vir Biotechnology director Janet Napolitano sold 3,200 shares of Common Stock in an open-market transaction at $9.45 per share.

Rhea-AI Filing Summary

Vir Biotechnology director Janet Napolitano sold 3,200 shares of Common Stock in an open-market transaction at $9.45 per share. After the sale, she directly holds 21,216 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 27, 2025.

Insights

Equity compensation and insider-trading analyst

Routine, pre-planned sale of a modest share block under a 10b5-1 plan.

Director Janet Napolitano executed an open-market sale of 3,200 shares of Vir Biotechnology Common Stock at $9.45 per share. This is reported as a standard sale transaction with no associated derivative exercises or complex instruments in this filing.

Following the sale, she continues to directly own 21,216 shares, indicating she retains a meaningful equity stake. The transaction was executed pursuant to a pre-established Rule 10b5-1 trading plan, which typically means the trade was scheduled in advance rather than timed opportunistically.

Because the sale is relatively limited in size and occurs under a 10b5-1 plan, it generally reads as routine portfolio management. Subsequent company filings may provide additional context if there are future plan-related transactions or changes in her overall holdings.

Insider Trade Summary 10b5-1

Net Seller: 3,200 shares

Net Sell 1 txn

Insider Napolitano Janet

Role Director

Sold 3,200 shs ($30K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,200	$9.45	$30K

Holdings After Transaction: Common Stock — 21,216 shares (Direct)

Footnotes (1)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 27, 2025.

Key Figures

Shares sold: 3,200 shares Sale price: $9.45 per share Shares held after transaction: 21,216 shares +2 more

5 metrics

Shares sold 3,200 shares Open-market sale of Common Stock

Sale price $9.45 per share Price for the 3,200-share sale

Shares held after transaction 21,216 shares Direct ownership following the sale

Transaction code S Sale in open market or private transaction

Trading plan adoption date June 27, 2025 Rule 10b5-1 trading plan adoption

Key Terms

Rule 10b5-1 trading plan, Form 4, open-market sale, Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Form 4 regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vir Biotechnology (VIR) report for Janet Napolitano?

Vir Biotechnology reported that director Janet Napolitano sold 3,200 shares of Common Stock. The shares were sold in an open-market transaction at $9.45 per share, as disclosed in a Form 4 insider trading report filed with regulators.

At what price did Janet Napolitano sell Vir Biotechnology (VIR) shares?

Janet Napolitano sold her Vir Biotechnology shares at $9.45 per share. The Form 4 specifies a single open-market sale of 3,200 shares of Common Stock at this price, detailing the transaction terms for investors monitoring insider activity.

How many Vir Biotechnology (VIR) shares does Janet Napolitano hold after the sale?

After the reported sale, Janet Napolitano directly holds 21,216 Vir Biotechnology shares. This post-transaction holding figure, disclosed in the Form 4, helps investors understand that she retains an ongoing equity stake in the company despite the recent sale.

Was Janet Napolitano’s Vir Biotechnology (VIR) share sale under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the sales were effected under a Rule 10b5-1 trading plan. That plan was adopted on June 27, 2025, indicating the transaction was pre-arranged rather than timed on the basis of new, discretionary decisions.

What type of transaction code appears on Janet Napolitano’s Vir Biotechnology (VIR) Form 4?

The Form 4 lists transaction code "S" for Janet Napolitano’s trade. This code indicates a sale in an open-market or private transaction, confirming that the filing reports a straightforward disposition of Common Stock rather than an option exercise or gift.

Does this Vir Biotechnology (VIR) Form 4 include any derivative security exercises?

No. The Form 4 transaction is categorized as non-derivative Common Stock with code "S" for sale. The derivative security summary is empty, showing there were no option exercises, conversions, or other derivative-related transactions reported in this particular filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 05:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Napolitano Janet

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		3,200	D	$9.45	21,216	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 27, 2025.

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)